Lazard Asset Management
PSTX

Lazard Asset Management’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Lazard Asset Management’s Portfolio PSTX Stock Details PSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-797
Closed -$7K – 2635
2024
Q4 		$7K Buy
797
+669
+523% +$3.49K ﹤0.01% 2121
2024
Q3 		$0 Sell
128
-203
-61% -$628 ﹤0.01% 2489
2024
Q2 		$0 Sell
331
-28,348
-99% -$77.5K ﹤0.01% 2464
2024
Q1 		$91K Buy
28,679
+21,138
+280% +$70.5K ﹤0.01% 1570
2023
Q4 		$24K Sell
7,541
-24,523
-76% -$63.2K ﹤0.01% 2039
2023
Q3 		$75K Buy
32,064
+13,966
+77% +$29.3K ﹤0.01% 1735
2023
Q2 		$31K Buy
18,098
+6,066
+50% +$15.5K ﹤0.01% 1992
2023
Q1 		$36K Sell
12,032
-4,912
-29% -$29.4K ﹤0.01% 1900
2022
Q4 		$89K Buy
+16,944
New +$77.5K ﹤0.01% 1573

Other funds holding PSTX

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Lazard Asset Management's PSTX Position: Q1 2025 in Review

Lazard Asset Management sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2025, closing a stake of 797 shares — an estimated $7K sold.

Lazard Asset Management first reported a position in PSTX in Q4 2022 and held it in 9 quarters. The position peaked at $91K in Q1 2024. 1 fund tracked by Wall St. Rank holds PSTX as of Q1 2025.

  • Lazard Asset Management reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • Lazard Asset Management sold 797 Poseida Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $7K.
  • Lazard Asset Management first reported a position in Poseida Therapeutics, Inc. Common Stock in Q4 2022 and held it in 9 quarters.
  • Lazard Asset Management's Poseida Therapeutics, Inc. Common Stock position peaked at $91K in Q1 2024.
  • 1 fund tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2025.

Based on Lazard Asset Management's 13F filing for Q1 2025, filed 15 May 2025.